Phase 1 study of patritumab deruxtecan (HER3-DXd; U3-1402) in combination with osimertinib in patients with advanced EGFR-mutated NSCLC

被引：0
|
作者：
Janne, Pasi A.
Mostillo, Joseph
Shrestha, Pomy
Zhang, Ruoyang
Fan, Pang-Dian
Cantero, Frederique
机构：
[1] Dana Farber Canc Inst, Lowe Ctr Thorac Oncol, Boston, MA USA
[2] Dana Farber Canc Inst, Boston, MA USA
[3] Daiichi Sankyo Inc, Basking Ridge, NJ USA
[4] Daiichi Sankyo, Basking Ridge, NJ USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS3161
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Phase 1 Study of Patritumab Deruxtecan (HER3-DXd; U3-1402) in Combination with Osimertinib in Patients with Locally Advanced or Metastatic EGFR-mutated NSCLC
    Janne, P.
    Rajagopalan, R.
    Pudussery, G.
    Shrestha, P.
    Chen, S.
    Hodge, R.
    Qiu, Y.
    Yu, C.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S237 - S237
  • [2] Dynamics of Molecular Markers in EGFR-Mutated NSCLC Patients Treated with Patritumab Deruxtecan (HER3-DXd; U3-1402)
    Janne, P.
    Baik, C.
    Hayashi, H.
    Su, W.
    Qi, Z.
    Enomoto, K.
    Karnoub, M.
    Yu, C.
    Qiu, Y.
    Yu, H. A.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S237 - S237
  • [3] Efficacy and Safety of the Novel HER3 Directed Antibody Drug Conjugate Patritumab Deruxtecan (HER3-DXd; U3-1402) in EGFR-mutated NSCLC
    Yu, H.
    Baik, C.
    Gold, K.
    Hayashi, H.
    Johnson, M.
    Koczywas, M.
    Murakami, H.
    Nishio, M.
    Steuer, C.
    Su, W.
    Yang, J. C.
    Karam, S.
    Qi, Z.
    Qiu, Y.
    Chen, S.
    Yu, C.
    Janne, P.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S107 - S107
  • [4] HERTHENA-Lung01: A Randomized Phase 2 Study of Patritumab Deruxtecan (HER3-DXd; U3-1402) in Previously Treated Metastatic EGFR-mutated NSCLC
    Janne, P.
    Johnson, M.
    Goto, Y.
    Yang, J. C.
    Karam, S.
    Chen, S.
    Qiu, Y.
    Yu, H.
    Yu, C.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S236 - S236
  • [5] Dynamics of HER3 and its correlated gene expression profile in EGFR-mutated NSCLC tumor treated with EGFR-TKI toward enhancing effectiveness of patritumab deruxtecan (HER3-DXd; U3-1402).
    Yonesaka, Kimio
    Tanizaki, Junko
    Maenishi, Osamu
    Haratani, Koji
    Kawakami, Hisato
    Tanaka, Kaoru
    Hayashi, Hidetoshi
    Sakai, Kazuko
    Chiba, Yasutaka
    Goto, Hiroki
    Otsuka, Eri
    Okida, Hiroaki
    Kobayashi, Maki
    Yoshimoto, Ryoto
    Funabashi, Masanori
    Hashimoto, Yuuri
    Hirotani, Kenji
    Kagari, Takashi
    Nishio, Kazuto
    Nakagawa, Kazuhiko
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [6] Translational insights and overall survival in the U31402-A-U102 study of patritumab deruxtecan (HER3-DXd) in EGFR-mutated NSCLC
    Yu, H. A.
    Baik, C.
    Kim, D. -W.
    Johnson, M. L.
    Hayashi, H.
    Nishio, M.
    Yang, J. C. -H.
    Su, W. -C.
    Gold, K. A.
    Koczywas, M.
    Smit, E. F.
    Steuer, C. E.
    Felip, E.
    Murakami, H.
    Kim, S. -W.
    Su, X.
    Sato, S.
    Fan, P. -D.
    Fujimura, M.
    Tanaka, Y.
    Patel, P.
    Sternberg, D. W.
    Sellami, D.
    Jaenne, P. A.
    ANNALS OF ONCOLOGY, 2024, 35 (05) : 437 - 447
  • [7] Updated efficacy and safety of patritumab deruxtecan (HER3-DXd; U3-1402), a HER3 directed antibody drug conjugate, in EGFRm NSCLC
    Hayashi, Hidetoshi
    Yu, Helena A.
    Baik, Christina
    Gold, Kathryn
    Johnson, Melissa L.
    Koczywas, Marianna
    Murakami, Haruyasu
    Nishio, Makoto
    Steuer, Conor
    Su, Wu-Chou
    Yang, James C. H.
    Karam, Samer
    Qui, Zhenhao
    Qiu, Yang
    Chen, Shuquan
    Yu, Channing
    Janne, Pasi A.
    ANNALS OF ONCOLOGY, 2021, 32 : S318 - S318
  • [8] HERTHENA-Lung01: a phase II study of patritumab deruxtecan (HER3-DXd) in previously treated metastatic EGFR-mutated NSCLC
    Yu, Helena A.
    Yang, James Chih-Hsin
    Hayashi, Hidetoshi
    Goto, Yasushi
    Felip, Enriqueta
    Reck, Martin
    Vigliotti, Michele
    Dong, Qian
    Cantero, Frederique
    Fan, Pang-Dian
    Kanai, Masayuki
    Sternberg, David W.
    Jaenne, Pasi A.
    FUTURE ONCOLOGY, 2023, 19 (19) : 1319 - 1329
  • [9] Efficacy and safety of patritumab deruxtecan (U3-1402), a novel HER3 directed antibody drug conjugate, in patients (pts) with EGFR-mutated (EGFRm) NSCLC
    Yu, H. A.
    Baik, C. S.
    Gold, K.
    Hayashi, H.
    Johnson, M.
    Koczywas, M.
    Murakami, H.
    Nishio, M.
    Steuer, C.
    Su, W-C.
    Yang, J.
    Karam, S.
    Qi, Z.
    Qiu, Y.
    Chen, S.
    Yu, C.
    Janne, P. A.
    ANNALS OF ONCOLOGY, 2020, 31 : S1189 - S1190
  • [10] An open-label, phase II study of patritumab deruxtecan (HER3-DXd, U3-1402) in patients (pts) with previously treated advanced/metastatic colorectal cancer (CRC).
    Raghav, Kanwal Pratap Singh
    Yoshino, Takayuki
    Taniguchi, Hiroya
    Tejpar, Sabine
    Vogel, Arndt
    Wainberg, Zev A.
    Yamaguchi, Kensei
    Kanai, Masayuki
    Liu Yali
    Mekan, Sabeen
    Pudussery, Geetha
    Qiu, Yang
    Kopetz, Scott
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
12345